Prof. Dr. Dr. med. Antonio Cozzio
chief physician
Dermatologie | Venerologie | Allergologie · Dept. IV
Real world utilization of upadacitinib in adult and adolescent patients living with moderate to severe atopic dermatitis (AD-VISE)
Feb 14, 2022
Clinical Studies - Feb 14, 2022 - Dec 31, 2025
Ongoing
Project leader: Cozzio Antonio
A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study
Jan 25, 2022
Clinical Studies - Jan 25, 2022 - Jan 25, 2022
Automatically Closed
Project leader: Cozzio Antonio
Efficacy and safety comparison of brodalumab versus guselkumab in adult subjects with moderate -to -severe plaque psoriasis and inadequate response to ustekinumab; COBRA / Phase 4 – efficacy trial A randomised, blinded, parallel-group, multi-site, clinical trial
Sep 13, 2021
Clinical Studies - Sep 13, 2021 - Nov 16, 2022
Completed
Project leader: Cozzio Antonio
Development of the European Organisation for Research and Treatment of Cancer (EORTC)/ Cutaneous Lymphoma Task Force (CLTF) questionnaire to assess HRQoL in cutaneous lymphoma
Feb 1, 2021
Clinical Studies - Feb 1, 2021 - Aug 25, 2023
Automatically Closed
Project leader: Cozzio Antonio
A multicentre, double blind, randomised, placebo-controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study
Jun 25, 2016
Clinical Studies - Jun 25, 2016 - Dec 31, 2027
Ongoing
Project leader: Cozzio Antonio
Swiss Dermatology Network for Targeted Therapies (SDNTT) Objective Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis with Biologics and Systemic Therapeutics based on PsoBest German Registry and in operational cooperation with CVderm in Hamburg
Jan 31, 2012
Clinical Studies - Jan 31, 2012 - Dec 31, 2030
Ongoing
Project leader: Cozzio Antonio